NCT05256017View on ClinicalTrials.gov

Safety and Tolerability Study of Acoziborole in g-HAT Seropositive Subjects

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

1,208

Participants

Timeline

Start Date

December 30, 2021

Primary Completion Date

August 3, 2023

Study Completion Date

August 3, 2023

Conditions
Trypanosomiasis, AfricanTrypanosoma Brucei Gambiense; InfectionSleeping Sickness
Interventions
DRUG

Acoziborole

Single dose administration of acoziborole (3 tablets of 320 mg) on Day 1

DRUG

Placebo

Single dose administration of placebo (3 tablets of 320 mg) on Day 1

Trial Locations (7)

Unknown

General Referral Hospital of Bagata, Bagata

Hospital of Dipumba, Mbuji-Mayi

General Referral Hospital of Idiofa, Idiofa

General Referral Hospital of Masi-Manimba, Masi-Manimba

General Referral Hospital of Kwamouth, Kwamouth

General Referral Hospital of Bandundu, Bandundu Province

General Referral Hospital of Dubreka, Dubréka

All Listed Sponsors
lead

Drugs for Neglected Diseases

OTHER

NCT05256017 - Safety and Tolerability Study of Acoziborole in g-HAT Seropositive Subjects | Biotech Hunter | Biotech Hunter